Spectral Medical Provides Tigris Trial Update

74 patients enrolled New sites to further accelerate patient enrollment On track to onboard seven new trial sites around the end of November 2023 TORONTO, Canada – October 3, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a a late-stage...
Read More

Spectral Medical Provides Board Update

TORONTO, Canada – October 2, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that John Nosenzo will be stepping down from Spectral...
Read More

Spectral Medical Supports World Sepsis Day

World Sepsis Day is Today, September 13, 2023 TORONTO, Canada – September 13, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to support...
Read More
Click to Hide Advanced Floating Content
EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.